On November 6, GENSCRIPT B-1K fell 13.54% in Regular Trading, trading at HK$28.88, with turnover of HK$197 million.
The most relevant recent company event is its announcement that associate Legend Biotech submitted a Form 6-K and will present multiple CARVYKTI studies at the American Society of Hematology annual meeting in December.
According to the company disclosure, the presentation package includes two oral presentations, two poster presentations and one electronic publication related to CARVYKTI in multiple myeloma. Recent company statements also said business and operations remain normal after clarifications around unusual price moves and trading-counter rumors. Given the lack of a newer fundamental disclosure tied directly to today's selloff, the available public information mainly indicates that the stock is still trading around expectations and risk digestion ahead of the December data release.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments